Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
Jennifer L. Anderson(MACOM (United States)), Noah Federman(University of California, Los Angeles)
Cited by 39
Related Papers
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
|Journal of Clinical Oncology|2024|36